Home > Newsletters > Drug Industry Daily > NIH Focus on Translational Medicine Will Hurt Drug Pipeline, Former Execs Say
Drug Industry Daily
April 20, 2011 | Vol. 10 No. 78
NIH Focus on Translational Medicine Will Hurt Drug Pipeline, Former Execs Say
JERSEY CITY, N.J. — Due to increasing pressures from Congress, the NIH is moving away from funding basic medical research and shifting toward translational work, a field once reserved for the pharmaceutical industry.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.